Genmab A-S
Suletud
1,865.5 0.24
Ülevaade
Aktsiahinna muutus
24h
Min
1863
Max
1873
Sissetulek | 83M 1.4B |
---|---|
Müük | 1.3B 5.4B |
P/E Sektori keskmine | 21.02 103.001 |
Aktsiakasum | 21.7 |
Kasumimarginaal | 26.074 |
EBITDA | 423M 2.1B |
Soovitused | Neutraalne |
---|---|
12 kuu keskmine prognoos | -1.49 downside |
Turukapital | -261M 122B |
---|---|
Eelmine avamishind | 1865.26 |
Eelmine sulgemishind | 1865.5 |
Genmab A-S Graafik
Seotud uudised
Genmab A-S Prognoos
Hinnasiht
By TipRanks
-1.49% langus
12 kuu keskmine prognoos
Keskmine 2,493.35 DKK -1.49%
Kõrge 3,320 DKK
Madal 308.417 DKK
Põhineb 7 Wall Streeti analüütiku instrumendi Genmab A-S 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Genmab A-S
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.